Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form

Cancer Research

Journal
uri icon
  • Overview
  • Identity
  • View All
scroll to property group menus

Overview

articles

  • YAP-Mediated Recruitment of YY1 and EZH2 Represses Transcription of Key Cell-Cycle Regulators.  80:2512-2522. 2020
  • The immunosuppressive microenvironment in BRCA1-IRIS-overexpressing TNBC tumors is induced by bidirectional interaction with tumor-associated macrophages.  80:1102-1117. 2020
  • MDM2 and MDM4 are therapeutic vulnerabilities in malignant rhabdoid tumors.  79:2404-2414. 2019
  • Mycand loss of p53 cooperate to drive formation of choroid plexus carcinoma.  79:2208-2219. 2019
  • PML Recruits TET2 to Regulate DNA Modification and Cell Proliferation in Response to Chemotherapeutic Agent.  78:2475-2489. 2018
  • Small-molecule activators of protein phosphatase 2A for the treatment of castration-resistant prostate cancer.  78:2065-2080. 2018
  • An Akt3 splice variant lacking the serine 472 phosphorylation site promotes apoptosis and suppresses mammary tumorigenesis.  78:103-114. 2018
  • Structurally novel antiestrogens elicit differential responses from constitutively active mutant estrogen receptors in breast cancer cells and tumors.  77:5602-5613. 2017
  • Targeting histone demethylases in MYC-driven neuroblastomas with ciclopirox.  77:4626-4638. 2017
  • Glioblastoma therapy can be augmented by targeting IDH1-mediated NADPH biosynthesis.  77:960-970. 2017
  • Spatial proximity to fibroblasts impacts molecular features and therapeutic sensitivity of breast cancer cells influencing clinical outcomes.  76:6495-6506. 2016
  • Metabolite and microbiome interplay in cancer immunotherapy.  76:6146-6152. 2016
  • RNA processing signatures of normal versus malignant progenitor cell aging predict leukemia stem cell sensitivity to RNA splicing modulation.  76. 2016
  • YAP mediates tumorigenesis in neurofibromatosis type 2 by promoting cell survival and proliferation through a COX-2-EGFR signaling axis.  76:3507-3519. 2016
  • Oncogenic mutation of AIMP2/p38 inhibits its tumor-suppressive interaction with Smurf2.  76:3422-3436. 2016
  • Fluorophore-NanoLuc BRET reporters enable sensitive in vivo optical imaging and flow cytometry for monitoring tumorigenesis.  75:5023-5033. 2015
  • Androgen receptor upregulation mediates radioresistance after ionizing radiation.  75:4688-4696. 2015
  • Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics.  75:296-305. 2015
  • Harnessing the fcμ receptor for potent and selective cytotoxic therapy of chronic lymphocytic leukemia.  74:7510-7520. 2014
  • Oncogenic KRAS confers chemoresistance by upregulating NRF2.  74:7430-7441. 2014
  • Androgen receptor splice variants determine taxane sensitivity in prostate cancer.  74:2270-2282. 2014
  • Bufalin is a potent small-molecule inhibitor of the steroid receptor coactivators SRC-3 and SRC-1.  74:1506-1517. 2014
  • Blocking lactate export by inhibiting the Myc target MCT1 disables glycolysis and glutathione synthesis.  74:908-920. 2014
  • Tumor suppressor NF2/Merlin is a microtubule stabilizer.  74:353-362. 2014
  • NSD2 is recruited through its PHD domain to oncogenic gene loci to drive multiple myeloma.  73:6277-6288. 2013
  • Notch1 is required for Kras-induced lung adenocarcinoma and controls tumor cell survival via p53.  73:5974-5984. 2013
  • Tumor MMP-1 activates endothelial PAR1 to facilitate vascular intravasation and metastatic dissemination.  73:4196-4211. 2013
  • Spreaders and sponges define metastasis in lung cancer: A Markov chain mathematical model.  73:2760-2769. 2013
  • Spreaders and sponges define metastasis in lung cancer: A markov chain mathematical model 2013
  • Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR..  73:2574-2586. 2013
  • Twist1 induces CCL2 and recruits macrophages to promote angiogenesis.  73:662-671. 2013
  • Perturbation of Rb, p53, and Brca1 or Brca2 cooperate in inducing metastatic serous epithelial ovarian cancer.  72:4141-4153. 2012
  • Fra-1 promotes breast cancer chemosensitivity by driving cancer stem cells from dormancy.  72:3451-3456. 2012
  • Parkin pathway activation mitigates glioma cell proliferation and predicts patient survival.  72:2543-2553. 2012
  • Bmk1 kinase suppresses epithelial-mesenchymal transition through the akt/gsk3 beta signaling pathway.  72:1579-1587. 2012
  • Use of multifunctional sigma-2 receptor ligand conjugates to trigger cancer-selective cell death signaling.  72:201-209. 2012
  • Tissue factor-activated coagulation cascade in the tumor microenvironment is critical for tumor progression and an effective target for therapy.  71:6492-6502. 2011
  • Targeted therapeutic remodeling of the tumor microenvironment improves an her-2 DNA vaccine and prevents recurrence in a murine breast cancer model.  71:5688-5696. 2011
  • Diagnosis of prostate cancer using differentially expressed genes in stroma.  71:2476-2487. 2011
  • Estrogen-related receptor gamma promotes mesenchymal-to-epithelial transition and suppresses breast tumor growth.  71:2518-2528. 2011
  • Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions.  71:496-505. 2011
  • Genotypes of nk cell kir receptors, their ligands, and fc gamma receptors in the response of neuroblastoma patients to hu14.18-il2 immunotherapy.  70:9554-9561. 2010
  • CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes.  70:8368-8377. 2010
  • The miR-17-92 cluster of microRNAs confers tumorigenicity by inhibiting oncogene-induced senescence.  70:8547-8557. 2010
  • Steroid receptor coactivator-3 expression in lung cancer and its role in the regulation of cancer cell survival and proliferation.  70:6477-6485. 2010
  • Notch1 functions as a tumor suppressor in a model of K-ras-induced pancreatic ductal adenocarcinoma.  70:4280-4286. 2010
  • EZH2 is essential for glioblastoma cancer stem cell maintenance.  69:9211-9218. 2009
  • Immunodetection of DNA repair endonuclease ERCC1-XPF in human tissue.  69:6831-6838. 2009
  • Loss of retinal cadherin facilitates mammary tumor progression and metastasis.  69:5030-5038. 2009
  • Combined integrin phosphoproteomic analyses and small interfering RNA-based functional screening identify key regulators for cancer cell adhesion and migration.  69:3713-3720. 2009
  • CDC25B mediates rapamycin-induced oncogenic responses in cancer cells.  69:2663-2668. 2009
  • C-1027, a radiomimetic enediyne anticancer drug, preferentially targets hypoxic cells.  69:593-598. 2009
  • Targeting ornithine decarboxylase impairs development of mycn-amplified neuroblastoma.  69:547-553. 2009
  • A human antibody-drug conjugate targeting EphA2 inhibits tumor growth in vivo.  68:9367-9374. 2008
  • Validation of the p21-activated kinases as targets for inhibition in neurofibromatosis type.  68:7932-7937. 2008
  • Protease-activated receptor (par) 2, but not par1, signaling promotes the development of mammary adenocarcinoma in polyoma middle t mice.  68:7219-7227. 2008
  • OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor.  68:5206-5215. 2008
  • The novel polyamine analogue CGC-11093 enhances the antimyeloma activity of bortezomib.  68:4783-4790. 2008
  • Targeting CUB domain-containing protein 1 with a monoclonal antibody inhibits metastasis in a prostate cancer model.  68:3759-3766. 2008
  • Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity.  68:2366-2374. 2008
  • Prediction of cancer driver mutations in protein kinases.  68:1675-1682. 2008
  • Genetic alterations in the tyrosine kinase transcriptome of human cancer cell lines.  67:11368-11376. 2007
  • Interaction of the tumor metastasis suppressor nonmetastatic protein 23 homologue H1 and estrogen receptor alpha alters estrogen-responsive gene expression.  67:10600-10607. 2007
  • Fbxw7/hcdc4 is a general tumor suppressor in human cancer.  67:9006-9012. 2007
  • Requirement for Rac1 in a K-ras-induced lung cancer in the mouse.  67:8089-8094. 2007
  • Histone deacetylase inhibitors enhance lexaturnurnab-induced apoptosis via a p21(cip1)-dependent decrease in survivin levels.  67:6987-6994. 2007
  • Fractalkine (cx3cl1)- and interleukin-2-enriched neuroblastoma microenvironment induces eradication of metastases mediated by t cells and natural killer cells.  67:2331-2338. 2007
  • Adaptation of energy metabolism in breast cancer brain metastases.  67:1472-1486. 2007
  • Pea-15 inhibits tumor cell invasion by binding to extracellular signal-regulated kinase 1/2.  67:1536-1544. 2007
  • Single chemical modifications of the c-1027 enediyne core, a radiomimetic antitumor drug, affect both drug potency and the role of ataxia-telangiectasia mutated in cellular responses to DNA double-strand breaks.  67:773-781. 2007
  • An antagonist of dishevelled protein-protein interaction suppresses beta-catenin-dependent tumor cell growth.  67:573-579. 2007
  • Activation of cancer cell migration and invasion by ectopic synthesis of coagulation factor vii.  66:9453-9460. 2006
  • Proteasome inhibitor drugs on the rise.  66:7840-7842. 2006
  • Detection of low molecular weight derivatives of cyclin e1 is a function of cyclin e1 protein levels in breast cancer.  66:7355-7360. 2006
  • Estrogen induces lung metastasis through a host compartment-specific response.  66:3667-3672. 2006
  • Hypoxic culture induces expression of sialin, a sialic acid transporter, and cancer-associated gangliosides containing non-human sialic acid on human cancer cells.  66:2937-2945. 2006
  • Targeting cell-impermeable prodrug activation to tumor microenvironment eradicates multiple drug-resistant neoplasms.  66:970-980. 2006
  • Unexpected effect of matrix metalloproteinase down-regulation on vascular intravasation and metastasis of human fibrosarcoma cells selected in vivo for high rates of dissemination.  65:10959-10969. 2005
  • Tid1 negatively regulates the migratory potential of cancer cells by inhibiting the production of interieukin-8.  65:8784-8791. 2005
  • The ability of E1A to rescue ras-induced premature senescence and confer transformation relies on inactivation of both p300/CBP and Rb family proteins.  65:8298-8307. 2005
  • Big mitogen-activated protein kinase 1/extracellular signal-regulated kinase 5 signaling pathway is essential for tumor-associated angiogenesis.  65:7699-7706. 2005
  • Immunostimulatory effects of low-dose cyclophosphamide are controlled by inducible nitric oxide synthase.  65:5027-5030. 2005
  • A DNA vaccine targeting fos-related antigen 1 enhanced by il-18 induces long-lived t-cell memory against tumor recurrence.  65:3419-3427. 2005
  • Haploinsufficiency for odc modifies mouse skin tumor susceptibility.  65:1146-1149. 2005
  • Targeting tumor angiogenesis with adenovirus-delivered anti-Tie-2 intrabody.  65:972-981. 2005
  • A DNA vaccine targeting survivin combines apoptosis with suppression of angiogenesis in lung tumor eradication.  65:553-561. 2005
  • Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway.  65:605-612. 2005
  • A selective tumor microvasculature thrombogen that targets a novel receptor complex in the tumor angiogenic microenvironment.  65:11109-11117. 2005
  • Host acid sphingomyelinase regulates microvascular function not tumor immunity.  64:8285-8291. 2004
  • Tid1, the human homologue of a Drosophila tumor suppressor, reduces the malignant activity of ErbB-2 in carcinoma cells.  64:7732-7739. 2004
  • Id2 is dispensable for myc-induced lymphomagenesis.  64:7296-7301. 2004
  • Lysophosphatidic acid stimulates ovarian cancer cell migration via a Ras-MEK kinase 1 pathway.  64:4209-4217. 2004
  • Mutation of hcdc4 leads to cell cycle deregulation of cyclin e in cancer.  64:795-800. 2004
  • Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity.  63:6378-6386. 2003
  • Differential role of tissue factor pathway inhibitors 1 and 2 in melanoma vasculogenic mimicry.  63:5381-5389. 2003
  • Overexpression of legumain in tumors is significant for invasion/metastasis and a candidate enzymatic target for prodrug therapy.  63:2957-2964. 2003
  • A quantitative analysis of rate-limiting steps in the metastatic cascade using human-specific real-time polymerase chain reaction.  62:7083-7092. 2002
  • Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs.  62:6938-6943. 2002
  • Interleukin 18 gene transfer expands the repertoire of antitumor Th1-type immunity elicited by dendritic cell-based vaccines in association with enhanced therapeutic efficacy.  62:5853-5858. 2002
  • Prostate-specific membrane antigen directed selective thrombotic infarction of tumors.  62:5470-5475. 2002
  • Hcdc4 gene mutations in endometrial cancer.  62:4535-4539. 2002
  • Loss of bax alters tumor spectrum and tumor numbers in arf-deficient mice.  62:2184-2191. 2002
  • Up-regulation of vascular endothelial growth factor by membrane-type 1 matrix metalloproteinase stimulates human glioma xenograft growth and angiogenesis.  62:580-588. 2002
  • A novel vascular endothelial growth factor heparin-binding domain substructure binds to glycosaminoglycans in vivo and localizes to tumor microvascular endothelium.  62:7118-7123. 2002
  • Mig (cxcl9) chemokine gene therapy combines with antibody-cytokine fusion protein to suppress growth and dissemination of murine colon carcinoma.  61:8498-8503. 2001
  • Transforming growth factor-beta 1 increases survival of human melanoma through stroma remodeling.  61:8306-8316. 2001
  • UV-induced DNA damage and mutations in Hupki (human p53 knock-in) mice recapitulate p53 hotspot alterations in sun-exposed human skin.  61:8158-8163. 2001
  • A proapoptotic peptide for the treatment of solid tumors.  61:7709-7712. 2001
  • Molecular classification of human carcinomas by use of gene expression signatures.  61:7388-7393. 2001
  • Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer.  61:5974-5978. 2001
  • Targeted interleukin 2 therapy enhances protective immunity induced by an autologous oral DNA vaccine against murine melanoma.  61:6178-6184. 2001
  • The level of mhc class i expression on murine adenocarcinoma can change the antitumor effector mechanism of immunocytokine therapy.  61:1500-1507. 2001
  • Early p53-positive foci as indicators of tumor risk in ultraviolet-exposed hairless mice: Kinetics of induction, effects of DNA repair deficiency, and p53 heterozygosity.  61:977-983. 2001
  • The oncogenic potential of the high mobility group box protein sox3.  60:6303-6306. 2000
  • Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.  60:4838-4844. 2000
  • Cc chemokine receptor-7 on dendritic cells is induced after interaction with apoptotic tumor cells: Critical role in migration from the tumor site to draining lymph nodes.  60:2209-2217. 2000
  • The polyamine oxidase inhibitor mdl-72,527 selectively induces apoptosis of transformed hematopoietic cells through lysosomotropic effects.  59:4944-4954. 1999
  • Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12.  59:4035-4041. 1999
  • Eukaryotic expression cloning with an antimetastatic monoclonal antibody identifies a tetraspanin (peta-3/cd151) as an effector of human tumor cell migration and metastasis.  59:3812-3820. 1999
  • Induction of persistent tumor-protective immunity in mice cured of established colon carcinoma metastases.  58:3918-3925. 1998
  • Remodeling of collagen matrix by human tumor cells requires activation and cell surface association of matrix metalloproteinase-2.  58:3743-3750. 1998
  • Targeted therapy with a novel enediyene antibiotic calicheamicin theta(i)(1) effectively suppresses growth and dissemination of liver metastases in a syngeneic model of murine neuroblastoma.  58:2925-2928. 1998
  • Tumor efficacy and bone marrow-sparing properties of TER286, a cytotoxin activated by glutathione S-transferase.  58:2568-2575. 1998
  • Stimulation of tumor growth by recombinant human insulin-like growth factor-i (igf-i) is dependent on the dose and the level of igf-i receptor expression.  58:3021-3027. 1998
  • Elimination of established murine colon carcinoma metastases by antibody-interleukin 2 fusion protein therapy.  57:4948-4955. 1997
  • Synergy between transforming growth factor α and hepatitis B virus surface antigen in hepatocellular proliferation and carcinogenesis.  57:3606-3611. 1997
  • Clinical significance of alpha(v)beta(3) integrin and intercellular adhesion molecule-1 expression in cutaneous malignant melanoma lesions.  57:1554-1560. 1997
  • Aberrant cell growth induced by avian winged helix proteins.  57:123-129. 1997
  • Differential and antagonistic effects of v-jun and c-jun.  56:4229-4235. 1996
  • Human dendritic cells genetically engineered to express high levels of the human epithelial tumor antigen mucin (MUC-1).  56:3763-3770. 1996
  • Involvement of b lymphocytes in the growth inhibition of human pulmonary melanoma metastases in athymic nu/nu mice by in antibody-lymphotoxin fusion protein.  56:1707-1712. 1996
  • C-fos is not essential for v-abl-induced lymphomagenesis.  55:6196-6199. 1995
  • The oncogene qin codes for a transcriptional repressor.  55:5540-5544. 1995
  • Therapeutic efficacy of a doxorubicin immunoconjugate in a preclinical model of spontaneous metastatic human-melanoma.  55:2352-2356. 1995
  • Tissue factor-initiated thrombin generation activates the signaling thrombin receptor on malignant-melanoma cells.  55:1629-1632. 1995
  • Effect of tissue inhibitor of the matrix metalloproteinases-2 expression on the growth and spontaneous metastasis of a human-melanoma cell-line.  54:5467-5473. 1994
  • Antiproliferative effects of enediynes on aids-derived kaposis-sarcoma cells.  54:4270-4273. 1994
  • Expression and cellular localization of messenger RNA for plasminogen activator inhibitor type 1 in human astrocytomas in vivo.  54:3329-3332. 1994
  • Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo.  54:182-189. 1994
  • Human cytotoxic t-cells suppress the growth of spontaneous melanoma metastases in scid/hu mice.  53:4933-4937. 1993
  • Contribution of glutathione transferase M3-3 to 1,3-bis(2-chloroethyl)-1-nitrosourea resistance in a human non-small cell lung cancer cell line.  53:4257-4261. 1993
  • Melanoma-mediated dissolution of extracellular-matrix - contribution of urokinase-dependent and metalloproteinase-dependent proteolytic pathways.  53:693-700. 1993
  • Tumor necrosis factor alpha and interleukin 1 alpha induce anchorage independence in v-jun transgenic murine cells.  53:615-621. 1993
  • A mechanism for neutrophil-mediated lysis of human neuroblastoma-cells.  53:362-367. 1993
  • Epstein-Barr virus-induced human B-cell lymphomas in SCID mice reconstituted with human peripheral blood leukocytes.  52:S5552-S5553. 1992
  • Cytogenetic characterization of B-cell lymphomas from severe combined immunodeficiency disease mice given injections of lymphocytes from Epstein-Barr virus-positive donors.  52:4678-4681. 1992
  • Long-term growth suppression of human glioma xenografts by chemoimmunoconjugates of 4-desacetylvinblastine-3-carboxyhydrazide and monoclonal-antibody 9.2.27.  52:3838-3844. 1992
  • Expression of glutathione transferase pi as a predictor for treatment results at different stages of acute nonlymphoblastic leukemia.  52:3281-3285. 1992
  • Multiple oncogenes and tumor suppressor genes are structurally and functionally intact during hepatocarcinogenesis in hepatitis B virus transgenic mice.  52:2823-2829. 1992
  • Heterogeneity among Epstein-Barr virus-seropositive donors in the generation of immunoblastic B-cell lymphomas in SCID mice receiving human peripheral blood leukocyte grafts.  52:2468-2477. 1992
  • Reactivation of insulin-like growth factor II during hepatocarcinogenesis in transgenic mice suggests a role in malignant growth.  52:2549-2556. 1992
  • Ascorbic acid enhances the effects of 6-hydroxydopamine and H2O2 on iron-dependent DNA strand breaks and related processes in the neuroblastoma cell line SK-N-SH.  51:6066-6072. 1991
  • Correlation of chondroitin sulfate proteoglycan expression on proliferating brain capillary endothelial-cells with the malignant phenotype of astroglial cells.  51:4986-4993. 1991
  • Suppression of spontaneous melanoma metastasis in scid mice with an antibody to the epidermal growth-factor receptor.  51:2193-2198. 1991
  • Synergy between hepatitis-B virus expression and chemical hepatocarcinogens in transgenic mice.  51:1278-1285. 1991
  • Effect of a chimeric antiganglioside gd2 antibody on cell-mediated lysis of human neuroblastoma-cells.  51:144-149. 1991
  • Sensitization of human melanoma cells to the cytotoxic effect of melphalan by the glutathione transferase inhibitor ethacrynic acid.  51:94-98. 1991
  • Glutathione transferase activity and isoenzyme composition in primary human breast cancers.  50:6848-6853. 1990
  • Increased lysis of melanoma by in vivo-elicited human lymphokine-activated killer cells after addition of antiganglioside antibodies in vitro.  50:6311-6315. 1990
  • Tumor promoter-stimulated mr92,000 gelatinase secreted by normal and malignant human-cells - isolation and characterization of the enzyme from ht1080 tumor-cells.  50:6162-6170. 1990
  • Biosynthesis and glycosylation of the carcinoma-associated antigen recognized by monoclonal-antibody ks1/4.  50:4656-4663. 1990
  • Phase I clinical comparative study of monoclonal antibody KS1/4 and KS1/4-methotrexate immunconjugate in patients with non-small cell lung carcinoma.  50:4154-9. 1990
  • Workshop report from the Division of Research Grants, National Institutes of Health. Molecular genetic approaches to the analysis of malignant transformation--a pathology B study section workshop.  50:3805-3806. 1990
  • Hepatocarcinogenesis due to chronic liver-cell injury in hepatitis-B virus transgenic mice.  50:3400-3407. 1990
  • Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2.  50:5234-5239. 1990
  • Functional-properties and effect on growth suppression of human neuro-blastoma tumors by isotype switch variants of monoclonal antiganglioside gd2 antibody 14.18.  49:2857-2861. 1989
  • Denitrosation of 1,3-bis(2-chloroethyl)-1-nitrosourea by class mu glutathione transferases and its role in cellular resistance in rat brain tumor cells.  49:2621-2625. 1989
  • Superiority of an acid-labile daunorubicin monoclonal antibody immunoconjugate compared to free drug.  48:6097-6102. 1988
  • Melanoma-associated gangliosides in the fish genus Xiphophorus.  48:3454-3460. 1988
  • Synthesis of nitrite and nitrate in murine macrophage cell lines.  47:5590-5594. 1987
  • Disialoganglioside-gd2 on human neuroblastoma-cells - target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor-growth.  47:1098-1104. 1987
  • Biosynthesis and expression of the disialoganglioside gd2, a relevant target antigen on small-cell lung-carcinoma for monoclonal antibody-mediated cytolysis.  46:5112-5118. 1986
  • Preclinical trials with combinations and conjugates of t101 monoclonal-antibody and doxorubicin.  46:4886-4891. 1986
  • Antigens associated with human squamous-cell lung-carcinoma defined by murine monoclonal-antibodies.  46:2970-2977. 1986
  • Differences in stereoselectivity and catalytic efficiency of three human glutathione transferases in the conjugation of glutathione with 7 beta,8 alpha-dihydroxy-9 alpha,10 alpha-oxy-7,8,9,10-tetrahydrobenzo(a)pyrene.  46:2220-2224. 1986
  • Fifth Annual Sapporo Cancer Seminar. Monoclonal antibodies: progress in cancer immunobiology and clinical application.  46:2193-2196. 1986
  • Antigens associated with a human-lung adenocarcinoma defined by monoclonal-antibodies.  44:681-687. 1984
  • Detection of ganglioside gd2 in tumor-tissues and sera of neuro-blastoma patients.  44:5914-5920. 1984
  • Fibronectin enhancement of directed migration of b-16 melanoma-cells.  44:1657-1663. 1984
  • Antinuclear, antinucleolar, and anticytoplasmic antibodies in patients with malignant melanoma.  43:1372-1380. 1983
  • Indirect immunofluorescence studies of proliferating cell nuclear antigen in nucleoli of human tumor and normal tissues.  43:3770-3777. 1983
  • Isolation and characterization of a cloned cell line R3327H-G8-A1 derived from the Dunning R3327H rat adenocarcinoma.  43:2167-2175. 1983
  • Response of human myeloid-leukemia cells to various sources of colony-stimulating activity and phytohemagglutinin-conditioned medium.  43:2350-2357. 1983
  • Stability, characterization, and kinetics of in-111-labeled monoclonal anti-tumor antibodies in normal animals and nude mouse-human tumor-models.  43:5347-5355. 1983
  • Statistical approach to immunosuppression classification using lymphocyte surface-markers and functional assays.  43:417-421. 1983
  • Benzo(a)pyrene metabolism by rat liver microsomes: effects of adding purified glutathione S-transferases A, B, and C.  42:4215-4221. 1982
  • Effect of 2,3,7,8-tetrachlorodibenzo-para-dioxin and phenobarbital on the occurrence and distribution of 4 cytochrome-P-450 isozymes in rabbit kidney, lung, and liver.  42:1423-1432. 1982
  • Effect of microsomal cytochrome P-450 isozyme induction on the mutagenic activation of 2-aminoanthracene.  42:1722-1726. 1982
  • Trans-epithelial invasion and intra-mesenchymal infiltration of the chick-embryo chorioallantois by tumor-cell lines.  42:1826-1837. 1982
  • Plasma-lipoproteins with bioregulatory properties including the capacity to regulate lymphocyte function and the immune-response.  41:3786-3788. 1981
  • Catalysis of divergent pathways of 2-acetylaminofluorene metabolism by multiple forms of cytochrome P-450.  40:4456-4459. 1980
  • Radioimmunoassay for tissue distribution of a human mammary tumor-specific glycoprotein.  40:662-666. 1980
  • Rapid, reversible rounding and aggregation of Rous sarcoma virus-infected chicken fibroblasts induced by a plasma macromolecule.  40:1753-1760. 1980
  • Subcellular-localization of the sedimentable form of mammary-tumor glycoprotein to the tumor-cell plasmalemma.  40:316-321. 1980
  • Frequency of association of mammary-tumor glycoprotein antigen and other markers with human-breast tumors.  39:2057-2061. 1979
  • Isolation and immunochemical characterization of antibodies from the sera of cancer-patients which are reactive against human-melanoma cell-membranes by affinity chromatography.  39:1683-1695. 1979
  • Synergistic effect of tumor-virus transformation and tumor promoter treatment on production of plasminogen activator by chick-embryo fibroblasts.  38:4601-4609. 1978
  • Approaches for isolation of biologically functional tumor-associated antigens.  37:2860-2865. 1977
  • Clinical evaluation of serum c3dp levels in individuals with malignant diseases.  37:692-695. 1977
  • Immunosuppressive effects of 3-methylcholanthrene given intratracheally in various inbred strains of mice.  37:3892-3894. 1977
  • Enhancement of infectivity and oncogenicity of a murine leukemia-virus in adult mice by x-irradiation.  36:2090-2095. 1976
  • Purification of soluble human melanoma-associated antigens.  36:2360-2364. 1976
  • Delayed cutaneous hypersensitivity to cell-free tumor antigens.  33:199-202. 1973
  • Immunological reaction in keratoacanthoma, a spontaneously resolving skin tumor.  33:2030-2033. 1973
  • The cell surface in tumor virus infection.  23:1519-1527. 1963
scroll to property group menus

Identity

International Standard Serial Number (ISSN)

  • 0008-5472

Electronic International Standard Serial Number (EISSN)

  • 1538-7445

©2021 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support